ZA200108527B - Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy. - Google Patents

Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy. Download PDF

Info

Publication number
ZA200108527B
ZA200108527B ZA200108527A ZA200108527A ZA200108527B ZA 200108527 B ZA200108527 B ZA 200108527B ZA 200108527 A ZA200108527 A ZA 200108527A ZA 200108527 A ZA200108527 A ZA 200108527A ZA 200108527 B ZA200108527 B ZA 200108527B
Authority
ZA
South Africa
Prior art keywords
compound
angiotensin
antagonistic activity
retinopathy
composition according
Prior art date
Application number
ZA200108527A
Other languages
English (en)
Inventor
Shizue Nakagawa
Yasutaka Nagisa
Hitoshi Ikeda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ZA200108527B publication Critical patent/ZA200108527B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200108527A 1999-04-28 2001-10-17 Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy. ZA200108527B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12149899 1999-04-28

Publications (1)

Publication Number Publication Date
ZA200108527B true ZA200108527B (en) 2002-10-17

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108527A ZA200108527B (en) 1999-04-28 2001-10-17 Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy.

Country Status (23)

Country Link
US (2) US7064141B1 (cs)
EP (1) EP1197223B1 (cs)
KR (1) KR100865059B1 (cs)
CN (1) CN1172719C (cs)
AT (1) ATE289204T1 (cs)
AU (1) AU774799B2 (cs)
BR (1) BR0010084A (cs)
CA (1) CA2371554C (cs)
CZ (1) CZ301913B6 (cs)
DE (1) DE60018186T2 (cs)
DK (1) DK1197223T3 (cs)
ES (1) ES2233362T3 (cs)
HU (1) HU226948B1 (cs)
MX (1) MXPA01010923A (cs)
NO (1) NO327446B1 (cs)
NZ (1) NZ514855A (cs)
PL (1) PL196895B1 (cs)
PT (1) PT1197223E (cs)
RU (1) RU2239454C2 (cs)
SI (1) SI1197223T1 (cs)
SK (1) SK286859B6 (cs)
WO (1) WO2000066161A1 (cs)
ZA (1) ZA200108527B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
WO2003047573A1 (fr) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Agents pour améliorer l'état de résistance à l'insuline
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
JP4489020B2 (ja) * 2003-04-15 2010-06-23 第一三共株式会社 眼内血管新生性疾患の予防又は治療のための医薬
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
CA2576827A1 (en) * 2004-08-31 2006-03-09 Newsouth Innovations Pty Limited Vegf inhibition
DK1814527T4 (da) * 2004-11-05 2020-12-07 Boehringer Ingelheim Int Dobbeltlagstablet omfattende telmisartan og amlodipin
WO2006115185A1 (ja) * 2005-04-21 2006-11-02 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
WO2007066678A1 (ja) * 2005-12-06 2007-06-14 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
PE20090550A1 (es) * 2007-03-28 2009-06-01 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
GB9223860D0 (en) 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
MX9603259A (es) 1994-02-08 1997-03-29 Novartis Ag Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
DK0889880T3 (da) * 1996-03-29 2003-09-01 Smithkline Beecham Corp Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering
AU713277B2 (en) 1996-04-05 1999-11-25 Takeda Pharmaceutical Company Limited Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity
TW416953B (en) * 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0991647B1 (en) * 1997-06-27 2002-09-04 Smithkline Beecham Corporation Eprosartan monohydrate
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
CA2299470C (en) * 1997-08-06 2010-01-26 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
ES2214013T3 (es) 1998-03-04 2004-09-01 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
SK285863B6 (sk) * 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
JP2000159671A (ja) 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Also Published As

Publication number Publication date
CA2371554C (en) 2009-06-09
KR20020015315A (ko) 2002-02-27
DE60018186T2 (de) 2005-12-29
NO327446B1 (no) 2009-06-29
WO2000066161A1 (fr) 2000-11-09
RU2239454C2 (ru) 2004-11-10
US7064141B1 (en) 2006-06-20
EP1197223A1 (en) 2002-04-17
HU226948B1 (en) 2010-03-29
DE60018186D1 (de) 2005-03-24
NO20015257L (no) 2001-10-26
PL350554A1 (en) 2002-12-16
DK1197223T3 (da) 2005-05-30
AU774799B2 (en) 2004-07-08
HUP0200890A2 (hu) 2002-11-28
HUP0200890A3 (en) 2002-12-28
CZ20013804A3 (cs) 2002-04-17
CN1172719C (zh) 2004-10-27
NZ514855A (en) 2004-01-30
NO20015257D0 (no) 2001-10-26
CZ301913B6 (cs) 2010-07-28
CA2371554A1 (en) 2000-11-09
SI1197223T1 (cs) 2005-08-31
EP1197223A4 (en) 2003-10-29
KR100865059B1 (ko) 2008-10-23
PL196895B1 (pl) 2008-02-29
ATE289204T1 (de) 2005-03-15
PT1197223E (pt) 2005-04-29
MXPA01010923A (es) 2002-06-21
BR0010084A (pt) 2002-01-15
EP1197223B1 (en) 2005-02-16
US20060189669A1 (en) 2006-08-24
ES2233362T3 (es) 2005-06-16
AU4143400A (en) 2000-11-17
CN1348385A (zh) 2002-05-08
SK15452001A3 (sk) 2002-04-04
SK286859B6 (sk) 2009-06-05

Similar Documents

Publication Publication Date Title
DE60314155T2 (de) Neue ppar-liganden, die keine flüssigkeitsretention, ödem oder dekompensierte herzinsuffizienz verursachen
ZA200108527B (en) Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy.
DE602004005720T2 (de) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imidazol-2-thion als nicht-sedierender alpha 2a agonist
EP2716302B1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
DE60037192T2 (de) Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens
FR2742052A1 (fr) Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
AU754852B2 (en) Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
WO1995001176A1 (en) Use of an angiotensin ii antagonist as an ocular hypotensive agent
WO2014186134A1 (en) Compositions and methods for hair growth
CA2522318C (en) Drug for preventing or treating angiogenic eye diseases
KR20080053950A (ko) 오르토 치환 아닐린 유도체 및 항산화약
CA2557392A1 (en) Preventive or therapeutic agents for severe diabetic retinopathy
CN100558359C (zh) 肾小球病治疗剂
WO2009087900A1 (ja) 眼内血管透過性亢進を伴う疾患の予防または治療のための医薬
WO2000002556A1 (fr) Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour la fabrication d'un medicament pour traiter les glomerulonephrites chroniques
HK1080753A (en) Drug for preventing or treating angiogenic eye diseases
AU1955000A (en) Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
HK1108832A (en) Remedy for glomerular diseae